Phage Futures Congress 2024 | Kisaco Research | 19 November 2024 | TBA, Boston, USA

This is your leading phage therapy networking platform to address the critical challenges in regulation, manufacturing, investment, R&D, and commercial landscapes.

The all-new agenda will focus on:
• Addressing the progress and need for phage therapeutic regulatory guidance including participation from the MHRA discussing standardization developments.
• Overcoming hurdles in phage manufacturing, developing solutions to endotoxicity and quality whilst platforming use cases of innovative technology e.g. artificial intelligence.
• Unparalleled opportunities to network with strategic partners, pharmaceutical companies, funders and investors to progress your business development and tackle commercial barriers.
• Major preclinical/clinical breakthroughs across human health, animal health, aquaculture, aquaculture, nutrition, and cosmetic industries.

2024 Speakers

Mimi Yen
CEO & Co-Founder, PhagePro Inc.

Anna Jacobs
Biologist, BARDA

Mayukh Das
Chief Operations Officer, Phiogen

Dylan Lawrence
Senior Scientist, Pfizer

Ashley Trama
Associate Vice President, Research and Development Program Management, Locus Biosciences

Matthew Dunne
Chief Scientific Officer, Micreos

Aristobulo Loaiza
CEO, Hedros Bio

Matthew Tebeau
Chief Operating Officer, Phagelux

Amanda Bukardt
Chief Executive Officer, Phiogen

Danielle Peters
Research Officer, National Research Council Canada

Joseph Campbell
Program Officer, ex-NIH

Laura Kovanda
Executive Director, Astellas

Chrysi Sergaki
Microbiome Group Leader, MHRA